David A. Siegel Aerie Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $507,052 - $1.21 Million	79,600 Added 434.97%	97,900 $1.48 Million
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $67,320 - $124,576	-13,600 Reduced 42.63%	18,300 $137,000
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $18,612 - $32,340	-3,300 Reduced 9.38%	31,900 $290,000
Q4 2021 Feb 14, 2022	SELL	$7.02 - $13.33 $1.41 Million - $2.67 Million	-200,600 Reduced 85.07%	35,200 $247,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $636,184 - $934,606	-56,200 Reduced 19.25%	235,800 $2.69 Million
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $2.58 Million - $3.23 Million	170,400 Added 140.13%	292,000 $4.68 Million
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $1.6 Million - $2.54 Million	121,600 New	121,600 $2.17 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.